| 心血管疾病常用药的药物基因组学最新研究进展 |
| |
| 引用本文： | 周小红, 钟诗龙. 心血管疾病常用药的药物基因组学最新研究进展[J]. 药学进展, 2018, 42(4): 269-283. |
| |
| 作者姓名： | 周小红 钟诗龙 |
| |
| 作者单位： | 1.广东省心血管病研究所广东省冠心病防治研究重点实验室，广东 广州 510080;2.广东省人民医院(广东省医学科学院)医学研究部，广东 广州 510080 |
| |
| 基金项目： | 国家重点研发计划(No.2017YFC0909301，No.2017YFC0909302，No.2017YFC0909303)；国家自然科学基金(No.81673514，No.81373486)；广东省科技计划项目基金(No.2016B090918114) |
| |
| 摘 要： | 心血管疾病是人类最主要的死亡原因之一，也是消耗巨大医疗资源的疾病之一。合理药物治疗是心血管疾病治疗的基石，但是心血管疾病治疗药物的疗效和安全性存在较大个体差异。重点讨论一些证据比较明确的基因变异对β阻滞剂、他汀类药物、氯吡格雷、阿司匹林、华法林、抗心律失常药、噻嗪类利尿药的药动学、药效学以及临床终点事件和毒副反应的影响。综述心血管疾病常用药在药物基因组学方面的最新研究进展，为基于基因检测的个体化用药提供参考。
|
| 关 键 词： | 心血管疾病 药物基因组学 个体化用药 疗效 安全性 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.U.S.Carvedilol Heart Failure Study Group |
| |
| ZHOU Xiaohong, ZHONG Shilong. Research Progress in the Pharmacogenomics of Common Cardiovascular Drugs[J]. Progress in Pharmaceutical Sciences, 2018, 42(4): 269-283. |
| |
| Authors: | ZHOU Xiaohong ZHONG Shilong |
| |
| Affiliation: | 1.Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangzhou 510080, China;2.Medical Research Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China |
| |
| Abstract: | Cardiovascular disease is one of the most important causes of death and consumes huge medical resources.Rational drug therapy is the cornerstone of the treatment of cardiovascular disease, but there are significant individual differences in the efficacy and safety of cardiovascular drugs.This article focuses on the effects of some relatively well-documented gene mutations on the pharmacokinetics, pharmacodynamics, clinical endpoint and side effects of beta blockers, statins, clopidogrel, aspirin, warfarin, antiarrhythmic agents, and piperazine diuretics.The latest research progress in the pharmacogenomics of cardiovascular drugs was reviewed, providing reference for genome sequencing-based personalized medicine. |
| |
| Keywords: | cardiovascular disease pharmacogenomics personalized medicine efficacy safety |
|
| 点击此处可从《药学进展》浏览原始摘要信息 |
|
点击此处可从《药学进展》下载全文 |
